|
Mr. Singh has been working with life science companies for over 15 years. He joined us in 2001 and serves as Chief Business Officer and General Counsel of Cato Research, Managing Principal of Cato BioVentures, and Chief Operating Officer and General Counsel of Cato Holding Company. Mr. Singh also serves on the senior management team and Board of Directors of Cato BioVentures' majority-owned and major interest portfolio companies, including Durham Pharmaceuticals (President), Hemodynamic Therapeutics (Chief Executive Officer), and VistaGen Therapeutics (Chief Operating Officer). In addition, Mr. Singh regularly provides strategic advice to senior management of sponsors with whom Cato Research and Cato BioVentures have a strategic development partnership (Strategic Master Services Agreement), especially guidance regarding corporate finance, corporate partnering and product acquisition opportunities. Cato Research is a founding member of Intuitive Partners LLC, a new consortium of leading professional service providers supporting early-stage life science companies. Intuitive Partners is the General Partner of the Celerity Fund, a new model investment fund focused on start-up and early-stage life science companies located in low-to-moderate income (LMI) areas. Mr. Singh is a Managing Member of Intuitive Partners and the Celerity Fund and leads our activities with those strategic partners. Prior to joining us, Mr. Singh served as Chief Business Officer of SciClone Pharmaceuticals (Nasdaq: SCLN), founder and Managing Director of Start-Up-Law, President of Artemis Neuroscience and Corporate Finance Associate in the Silicon Valley offices of Morrison & Foerster, an international law firm. Mr. Singh is a member of the State Bar of California and is based in Silicon Valley | 